Quick Capital Discloses 9.9% Stake in Regen BioPharma (RGBPP)
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.
The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.
Positive
- Material ownership disclosed: 3,320,000 shares representing 9.9% of the class.
- Sole control clarity: Quick Capital reports sole voting and sole dispositive power over the shares.
- Passive filing: The filer classifies the statement as a Schedule 13G and certifies the position is not for changing control.
Negative
- None.
Insights
TL;DR: A passive investor discloses a near-10% stake with sole voting and dispositive power—material ownership but no stated intent to control.
Quick Capital, LLC’s reported 9.9% stake is material because it approaches double-digit ownership that often draws investor attention. The filing clearly states sole voting and dispositive power for all 3,320,000 shares, which means Quick Capital can unilaterally vote and sell these shares. The Schedule 13G classification and the certification language indicate the position is presented as passive, not seeking to change control. For investors, the key implications are transparency about a significant holder and clarity that no coalition or group is reported.
TL;DR: Governance impact is limited by the filer’s passive claim, but sole voting power at 9.9% warrants monitoring.
The disclosure shows no shared voting arrangements or group membership and explicitly disclaims acquisition for control purposes, consistent with a Schedule 13G passive filing. Sole voting power concentrated in one entity near 10% can influence shareholder votes if aligned with others, yet the filing contains no indication of activist intent or planned governance changes. This is a material ownership disclosure for governance assessment but contains no immediate red flags or specified governance actions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Quick Capital filing as an activist seeking to change control of Regen BioPharma?
What type of entity is the reporting person for RGBPP?
AI-generated analysis. How Rhea-AI works. Not financial advice.